U.S. FDA Remains Committed to Streamline & Accelerate Drug Development using Model-Informed Drug Development (MIDD) technology
![Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Present at B. Riley FBR Investor Conference on May 22, 2019
Shawn O’Connor, chief executive officer, will present at the 20th Annual B. Riley FBR Institutional Investor Conference on Wednesday, May 22, at 10:30 a.m. (PDT) in Room 8.
![Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Lisa LaVange, PhD, Appointed to Board of Directors of Simulations Plus
Brings 35+ Years of Industry and Regulatory Expertise to Board
![FDA Purchases Bundle of ADMET Predictor® Licenses](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
FDA Purchases Bundle of ADMET Predictor® Licenses
Center for Tobacco Products incorporates machine learning platform to assist toxicology research
![Simulations Plus Releases ADMET Predictor® Version 9.5](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases ADMET Predictor® Version 9.5
New machine learning models and novel analysis methods address customer requests
![Simulations Plus Reports Record Second Quarter FY2019 Revenue](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports Record Second Quarter FY2019 Revenue
Quarterly Revenues Up 15%; Board of Directors Announces Quarterly Dividend of $0.06 Per Share
![Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Sets Date for 2nd Quarter 2019 Earnings Release and Conference Call
Conference Call to be on Tuesday, April 9, 2019, at 4:15 PM ET
![DILIsym Awarded $1.5 Million Phase II NIH Grant](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Awarded $1.5 Million Phase II NIH Grant
Phase II Award of NIH Fast Track SBIR Grant for Drug-induced Kidney Injury Software, RENAsym™, Funds Development Over Next 20 Months
![Simulations Plus Releases DDDPlus™ Version 6](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Releases DDDPlus™ Version 6
New models for in vitro systems lead to improved inputs for GastroPlus® simulations
![DILIsym Services Inc. Initiates Development of IPFsym™](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Services Inc. Initiates Development of IPFsym™
New idiopathic pulmonary fibrosis QSP platform to enable more efficient drug development
![Simulations Plus Reports First Quarter FY2019 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports First Quarter FY2019 Financial Results
First quarter net revenues of $7.5 million reflecting 6.6% year over year growth. Board of Directors announces quarterly dividend of $0.06 per share
![DILIsym Services Inc. Releases DILIsym® Version 8A](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Services Inc. Releases DILIsym® Version 8A
Substantial update of liver safety software includes new science and practical extensions
![Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Report First Quarter Fiscal Year 2019 Financial Results
Conference Call to be on Wednesday, January 9, 2019, at 4:15 p.m. EST
![Simulations Plus Reports FY2018 and Fourth Quarter FY2018 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Reports FY2018 and Fourth Quarter FY2018 Financial Results
Simulations Plus today reported results for the 4th quarter and fiscal year 2018. FY18 revenues increased 23%; earnings per share increased 51.4%.
Full Fiscal Year Pharmaceutical Software and Services Revenues Up 22.9%; Earnings per share of $0.50, up 51.4% over prior year
![Simulations Plus to Report 4th Quarter and Fiscal Year 2018 Financial Results](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus to Report 4th Quarter and Fiscal Year 2018 Financial Results
Conference Call to be on Wednesday, November 14, 2018, at 4:15 PM ET
![DILIsym Services, an SLP Company, Launches Consortium for Drug-Related Kidney Injury](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
DILIsym Services, an SLP Company, Launches Consortium for Drug-Related Kidney Injury
RENAsym consortium will use QST to predict and investigate drug-induced kidney injury across various patient groups
![Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Announces Quarterly Cash Dividend of $0.06 per Share
Simulations Plus announced today that is board of directors has declared a cash dividend of $0.06 per share, to be distributed on Nov. 8, 2018.
![Simulations Plus Receives New Grant Award from the FDA](https://www.simulations-plus.com/wp-content/themes/simulations-plus/library/dist/img/default_square-large.jpg)
Simulations Plus Receives New Grant Award from the FDA
Simulations Plus today announced today a new funded cooperative agreement with the FDA to work on the GastroPlus dermal absorption/PBPK (TCAT) model.